Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06268717
Other study ID # 23-0316
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 17, 2023
Est. completion date October 17, 2025

Study information

Verified date February 2024
Source University of North Carolina, Chapel Hill
Contact Sarah McGill, MD
Phone +1 (919) 966-7047
Email mcgills@email.unc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a double-blind, crossover food challenge study using pork with and without α-gal in patients with a clinical diagnosis of gastrointestinal (GI)- α-gal allergy, and to investigate the pathophysiology underlying their symptoms.


Description:

Each participant will be randomized to undergo two double-blind food challenges with at least a 10-day washout period between the challenges. One food challenge will contain pork meat with alpha gal sugar; one challenge will contain pork meat without the alpha gal sugar. During the challenges, participants will drink lactulose and C13 mannitol dissolved in water. The principal investigator and clinical research coordinators will be blinded to the challenges during the course of the study. The metabolic kitchen and a delegated research staff member will be unblinded. On consenting patients, a transnasal upper endoscopy (TNE) will be performed on each challenge day, pre-challenge, at hour 0 and post-challenge, at hour 6. During the TNE, esophagus, stomach and small bowel samples will be collected. Gastrointestinal pathology samples will be evaluated for inflammatory cells and also biobanked for further messenger RNA (mRNA) sequencing studies. Blood and urine will be collected during each challenge. Samples will be transported to a lab and analyzed for tryptase, basophil activation, and lactulose/ mannitol levels.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date October 17, 2025
Est. primary completion date October 17, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - The subject is at least 18 years of age. - The subject has a history of gastrointestinal alpha-gal allergy defined by elevated test for a-gal allergy (a-gal IgE >0.1 U/L) due to complaints of either abdominal pain or discomfort, diarrhea, nausea with or without vomiting, or a combination of those complaints, within the last 5 years. The subjects must have experienced one or more of the four symptoms at least once monthly for at least two months. The subjects will fill out a symptom questionnaire of the presence of these four symptoms (abdominal pain or discomfort, diarrhea, nausea, vomiting), frequency and severity (mild, moderate, or severe) for the 3 months prior to diagnosis. - The subject has experienced symptomatic improvement on a mammalian meat-free diet over at least a month's time, defined by saying "yes" to the following question: "On the alpha-gal avoidant diet, have you had adequate relief of gastrointestinal symptoms?" - The subject has elevated a-gal IgE titer on screening for the trial if they do not have a positive titer within 3 months of enrollment. - The subject is willing to not take nonsteroidal anti-inflammatory medications, leukotriene modifiers or steroids 14 days prior to challenge. - The subject is willing to sign the informed consent form. Exclusion Criteria: - The subject has health conditions that would pose a significant threat in the face of anaphylaxis or treatment for anaphylaxis (e.g., cardiac disease, unstable angina pectoris, arrhythmias). - The subject is allergic to mannitol. - If female, the subject is pregnant. - The subject has a history of chronic GI conditions, including inflammatory bowel disease, celiac disease, chronic pancreatitis with continued symptoms (experience moderate-severe abdominal pain, diarrhea, or nausea/vomiting that occur more frequently than once weekly) - The subject has diarrhea (one or more loose stools that conform to the container), moderate to severe abdominal pain, or vomiting within 10 days prior to the challenge. - The subject has a history of severe allergic reaction on mammalian meat ingestion (respiratory distress, chest pain or cardiopulmonary compromise) - The subject is unwilling to receive intramuscular epinephrine. - The subject is anticipated to use omalizumab within 6 months of enrollment. - The subject is anticipated to use systemic steroids within 28 days of food challenge. - The subject is anticipated to use leukotriene modifier within 14 days of food challenge. - The subject is unable to not use nonsteroidal anti-inflammatory drugs for 14 days prior to challenge. Additional Exclusion Criteria for Subjects Undergoing Transnasal Endoscopy and Biopsy - Known conditions that are contraindications to transnasal endoscopy, or in the opinion of the investigator any condition that would interfere with the study objectives. - History of head and neck malignancy or anatomical deformities of the nasopharynx - Severe anxiety

Study Design


Intervention

Other:
Ground pork containing alpha-gal
150 grams of cooked, ground pork meat containing alpha-gal sugar eaten once
Pork meat not containing alpha-gal
150 grams of cooked, ground pork meat not containing alpha-gal sugar

Locations

Country Name City State
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill Revivicor, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Allergic reaction (food challenge positive) Presence of allergic reaction within 6 hours of the challenge. Reported as dichotomous: food challenge positive (reaction) or food challenge negative (no reaction). 6 hours post ingestion
Primary No allergic reaction (food challenge negative) No allergic reaction within 6 hours of the challenge. Reported as dichotomous: food challenge positive (reaction) or food challenge negative (no reaction). 6 hours post ingestion
Primary Lactulose excretion C13 mannitol quantification with high-performance liquid chromatography- C13 mannitol excreted in the urine in the six hours following ingestion will be measured as a marker of intestinal permeability. 0- 6 hours post ingestion
Primary C13 mannitol excretion C13 mannitol quantification with high-performance liquid chromatography- C13 mannitol excreted in the urine in the six hours following ingestion will be measured as a marker of intestinal permeability. 0-6 hours post ingestion
Primary Basophil activation threshold response at timepoint 0 Basophil activation threshold responses - peripheral blood basophils will be isolated and stimulated with mammal-based extracts to create a dose-response curve for concentrations of antigen leading to CD63 activation 0 hours (prior to ingestion)
Primary Basophil activation threshold response at 2 hours Basophil activation threshold responses - peripheral blood basophils will be isolated and stimulated with mammal-based extracts to create a dose-response curve for concentrations of antigen leading to CD63 activation. 2 hours post ingestion
Primary Basophil activation threshold response at 4 hours Basophil activation threshold responses - peripheral blood basophils will be isolated and stimulated with mammal-based extracts to create a dose-response curve for concentrations of antigen leading to CD63 activation. 4 hours post ingestion
Primary Basophil activation threshold response at 6 hours Basophil activation threshold responses - peripheral blood basophils will be isolated and stimulated with mammal-based extracts to create a dose-response curve for concentrations of antigen leading to CD63 activation. Results pre- and post- pork challenge will be compared to assess for changes in basophil responses 6 hours post ingestion
Primary Serum tryptase at timepoint 0 Serum tryptase- serum tryptase levels will be quantified. 0 hours (prior to ingestion)
Primary Serum tryptase at 2 hours Serum tryptase- serum tryptase levels will be quantified. 2 hours post ingestion
Primary Serum tryptase at 4 hours Serum tryptase- serum tryptase levels will be quantified. 4 hours post ingestion
Primary Serum tryptase at 6 hours Serum tryptase- serum tryptase levels will be quantified. 6 hours post ingestion
Primary Mast cell count on stomach biopsies (per high powered field (hpf)) The number of mast cells will be counted at high-powered field on biopsy specimens of the stomach. 6 hours post ingestion
Primary Mast cell count on small bowel biopsies (per high powered field (hpf)) The number of mast cells will be counted at high-powered field on biopsy specimens of the small bowel. 6 hours post ingestion
Primary Eosinophil cell count on stomach biopsies (per high powered field (hpf)) The number of eosinophil cells will be counted at high-powered field on biopsy specimens of the stomach. 6 hours post ingestion
Primary Eosinophil cell count on small bowel biopsies (per high powered field (hpf)) The number of eosinophil cells will be counted at high-powered field on biopsy specimens of the small bowel. 6 hours post ingestion
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A